filovirus
marburg
viru
ebola
viru
ebov
quickli
outpac
host
immun
respons
caus
hemorrhag
fever
result
case
fatal
rate
high
human
nearli
nonhuman
primat
develop
effect
therapeut
ebov
daunt
public
health
challeng
hamper
pauciti
knowledg
regard
filoviru
pathogenesi
report
describ
success
strategi
interf
ebov
infect
use
antisens
phosphorodiamid
morpholino
oligom
pmo
combin
ebovspecif
pmo
target
sequenc
viral
mrna
viral
protein
vp
rna
polymeras
l
protect
rodent
preand
postexposur
therapeut
regimen
prophylact
proofofprincip
trial
pmo
also
protect
rhesu
macaqu
lethal
ebov
infect
work
describ
may
contribut
develop
design
druggabl
countermeasur
filovirus
microbi
pathogen
citat
warfield
kl
swenson
dl
oling
gg
nichol
dk
pratt
wd
et
al
genespecif
countermeasur
ebola
viru
base
antisens
phosphorodiamid
morpholino
oligom
plo
pathog
develop
effect
countermeasur
filovirus
ebola
viru
ebov
marburg
viru
marv
longsought
difficult
endeavor
yield
littl
success
although
worst
outbreak
result
sever
hundr
death
worldwid
filovirus
consid
signific
global
health
threat
reservoir
remain
unknown
pathogen
extrem
deadli
highli
infecti
aerosol
anecdot
evid
use
marv
ebov
explor
potenti
biowarfar
agent
offens
program
former
soviet
union
filovirus
rel
simpl
virus
genom
consist
seven
gene
encod
nucleoprotein
np
glycoprotein
four
smaller
viral
protein
vp
rnadepend
rna
polymeras
l
protein
singl
strand
negativesens
rna
develop
effect
treatment
ebov
hinder
lack
clear
understand
filoviru
pathogenesi
dispar
anim
model
difficulti
danger
work
ebov
condit
although
signific
progress
toward
vaccin
develop
via
demonstr
protect
nonhuman
primat
ebov
ill
death
vaccin
fulfil
requir
ebov
countermeasur
administr
type
interferon
therapeut
vaccin
immun
globulin
ribavirin
nucleosid
analogu
somewhat
success
rodent
ebov
model
fail
benefit
ebovinfect
nonhuman
primat
ebov
frequent
caus
sever
dissemin
intravascular
coagul
administr
recombin
clot
inhibitor
recent
shown
protect
rhesu
monkey
appear
hostdirect
consequ
manag
diseas
alon
may
suffici
addit
wellorchestr
sequencespecif
attack
viral
replic
may
effect
success
antifiloviru
treatment
regimen
abil
virusspecif
antisens
oligonucleotid
inhibit
viral
growth
interf
translat
viral
rna
first
demonstr
sinc
remark
progress
made
modifi
oligonucleotid
increas
stabil
affin
deliveri
cell
phosphorodiamid
morpholino
oligom
pmo
subclass
antisens
agent
modifi
includ
phosphorodiamid
linkag
morpholin
ring
exhibit
limit
offtarget
effect
favor
base
stack
high
duplex
stabil
high
solubl
cell
permeabl
hybrid
complex
format
pmo
mrna
duplex
effect
block
translat
viral
rna
therebi
inhibit
viral
replic
antisens
pmo
effect
antivir
vesivirus
flavivirus
sar
coronaviru
success
inhibit
viral
replic
pmo
report
demonstr
vitro
yet
shown
anim
model
hypothes
pmo
inhibit
viral
mrna
translat
would
provid
protect
ebov
infect
order
test
hypothesi
pmo
design
inhibit
translat
mrna
ebov
l
figur
ebovspecif
pmo
demonstr
sequencespecif
inhibit
compar
pmo
molecul
marvspecif
sequenc
pmo
contain
ebovscrambl
sequenc
reporterbas
vitro
translat
assay
figur
inhibit
observ
scrambl
nonspecif
pmo
lm
concentr
ebov
l
rna
target
figur
determin
whether
ebovspecif
pmo
could
reduc
viral
propag
vitro
cell
pretreat
pmo
concentr
lm
infect
multipl
infect
treatment
ebov
lspecif
pmo
abl
consist
reduc
viral
titer
ebovinfect
cell
figur
combin
three
pmo
also
reduc
viral
titer
cell
show
enhanc
effect
compar
treatment
one
pmo
figur
assay
viral
titer
scrambl
pmotreat
cell
nearli
ident
observ
untreat
cell
pmo
caus
obviou
cytotox
concentr
use
assay
unpublish
data
evalu
vivo
efficaci
ebovspecif
pmo
first
determin
surviv
mice
treat
individu
pmo
h
h
challeng
plaqueform
unit
pfu
mouseadapt
ebov
three
pmo
exhibit
wide
rang
efficaci
lethal
ebov
infect
pmo
provid
nearli
complet
protect
mice
pretreat
twice
lg
dose
figur
p
pmo
treatment
versu
pb
treatment
contrast
despit
strong
activ
cellfre
translat
assay
lspecif
pmo
confer
surviv
treat
mice
dose
figur
p
dose
l
pmo
compar
pbstreat
mice
expect
treatment
mice
marburgspecif
l
pmo
provid
protect
ebov
figur
next
investig
whether
combin
pmo
could
enhanc
efficaci
found
lspecif
pmo
administ
togeth
h
h
lethal
ebov
challeng
result
robust
protect
dose
test
figur
p
respect
ebovspecif
pmotreat
mice
compar
pbstreat
mice
investig
use
pmo
postexposur
regimen
mice
treat
singl
dose
three
pmo
administ
h
ebov
infect
figur
pmotreat
ebovinfect
mice
fulli
protect
dose
lower
dose
postchalleng
treatment
provid
enhanc
protect
p
respect
pmotreat
mice
compar
pbstreat
mice
mice
receiv
singl
pmo
treatment
h
infect
show
similar
protect
p
respect
pmotreat
mice
compar
pbstreat
mice
singl
dose
pmo
hpi
use
highest
concentr
combin
pmo
complet
protect
ebovinfect
mice
singledos
therapeut
regimen
lower
pmo
dosag
provid
complet
protect
may
possibl
repeat
inject
lower
concentr
ebovspecif
pmo
could
provid
equival
protect
fewer
administr
higher
amount
importantli
multipl
inject
n
nonspecif
pmo
enhanc
surviv
ebovinfect
rodent
unpublish
data
examin
tissu
infect
show
treatment
mice
combin
ebovspecif
pmo
slow
viral
spread
compar
mice
treat
scrambl
pmo
infect
cell
easili
observ
spleen
mice
treat
scrambl
pmo
figur
wherea
ebovinfect
cell
could
found
spleen
antiebov
pmotreat
mice
figur
viral
inocul
ebov
infect
fulmin
spleen
ebov
scrambl
pmotreat
anim
unpublish
data
spread
liver
mice
treat
scrambl
combin
pmo
figur
howev
extent
infect
limit
ebovspecif
combin
pmotreat
mice
unlik
scrambl
pmotreat
mice
ebov
antigen
detect
within
hepatocyt
figur
viral
antigen
observ
kidney
day
howev
day
viral
antigen
readili
observ
kidney
scrambl
pmotreat
compar
combin
pmotreat
mice
unpublish
data
viral
titer
spleen
liver
kidney
pmotreat
ebola
viru
ebov
caus
highli
lethal
hemorrhag
fever
result
mortal
human
current
avail
vaccin
therapeut
treat
ebov
infect
date
multipl
preand
postexposur
therapeut
strategi
primarili
focus
bolster
host
immun
respons
inhibit
viral
replic
undertaken
limit
success
bavari
colleagu
report
develop
success
therapeut
regimen
ebov
infect
base
antisens
phosphorodiamid
morpholino
oligom
pmo
pmo
subclass
chemic
modifi
antisens
oligonucleotid
interfer
translat
viral
mrna
thu
inhibit
viral
amplif
use
cellfre
translat
system
cellbas
assay
surviv
studi
rodent
identifi
sever
efficaci
ebovspecif
pmo
prophylact
administr
combin
three
ebovspecif
pmo
specif
target
viral
polymeras
l
protect
rhesu
macaqu
lethal
ebov
infect
first
success
antivir
intervent
filovirus
nonhuman
primat
find
may
serv
basi
new
strategi
quickli
develop
virusspecif
therapi
defens
known
emerg
genet
engin
bioterror
threat
infect
anim
corrobor
observ
pattern
antigen
stain
within
tissu
figur
determin
whether
mice
treat
pmo
gener
immun
respons
ebov
test
ebovspecif
cellmedi
humor
immun
respons
wk
infect
mice
demonstr
cell
respons
multipl
ebovspecif
peptid
includ
np
sequenc
figur
unpublish
data
also
gener
strong
serum
ebovspecif
antibodi
respons
similar
postchalleng
antibodi
respons
mice
protect
therapeut
vaccin
contain
ebola
viruslik
particl
figur
find
gener
immun
respons
protect
pmotreat
mice
rechalleng
anoth
dose
pfu
ebov
wk
surviv
initi
challeng
mice
complet
protect
second
lethal
ebov
infect
figur
p
verifi
effect
pmo
treatment
anoth
ebov
anim
model
infect
guinea
pig
ebov
treat
singl
dose
pmo
combin
either
h
h
h
ebov
infect
figur
surviv
greatli
increas
guinea
pig
receiv
treatment
h
ebov
infect
p
compar
untreat
guinea
pig
contrast
guinea
pig
treat
h
infect
p
respect
compar
untreat
guinea
pig
mean
viral
titer
group
measur
dpi
close
mirror
surviv
rate
observ
figur
result
logist
regress
indic
reduct
viral
titer
signific
effect
surviv
outcom
pmotreat
guinea
pig
p
reduct
viral
titer
decreas
odd
surviv
challeng
odd
ratio
remain
determin
administr
multipl
larger
pmo
base
encourag
result
vitro
rodent
design
small
proofofconcept
trial
nonhuman
primat
rhesu
monkey
treat
pmo
n
combin
l
pmo
n
prior
ebov
infect
day
infect
figur
initi
studi
test
efficaci
pmo
compound
exhibit
highest
activ
mice
unfortun
pmotreat
monkey
well
untreat
control
monkey
die
within
timetodeath
expect
ebovinfect
rhesu
macaqu
day
respect
contrast
treatment
rhesu
macaqu
combin
l
pmo
show
substanti
efficaci
two
pmotreat
monkey
surviv
ebov
challeng
clinic
sign
beyond
mild
depress
day
figur
third
pmotreat
monkey
clear
ebov
infect
remain
avirem
day
figur
die
sever
bacteri
infect
evid
ongo
ebov
infect
day
figur
unpublish
data
fourth
pmotreat
monkey
succumb
ebov
infect
day
figur
three
control
monkey
use
experi
receiv
treatment
succumb
ebov
infect
day
sinc
pmo
alon
provid
protect
nonhuman
primat
data
suggest
combin
pmo
efficaci
singletarget
pmo
treatment
also
suggest
protect
combin
pmotreat
monkey
due
nonspecif
effect
pmo
administr
abl
identifi
earli
clinic
sign
laboratori
valu
correl
surviv
laboratori
test
close
predict
surviv
viral
titer
platelet
count
liverassoci
enzym
blood
monkey
surviv
infect
detect
viru
day
stark
contrast
pmotreat
monkey
surviv
littl
detect
viremia
day
figur
pmotreat
monkey
exhibit
thrombocytopenia
although
pmo
treat
monkey
surviv
platelet
count
much
time
figur
similarli
monkey
experienc
increas
liverassoci
enzym
level
includ
alkalin
phosphatas
howev
level
surviv
monkey
climb
high
succumb
infect
return
normal
level
within
month
ebov
infect
figur
unpublish
data
correl
found
surviv
multipl
hematolog
valu
bodi
temperatur
serum
cytokin
measur
human
kit
biosourc
camarillo
california
unit
state
fibrin
degrad
product
unpublish
data
importantli
pmo
administr
induc
earli
dpi
detect
serum
ifn
tnf
cytokin
nonhuman
primat
unpublish
data
indic
protect
like
due
nonspecif
effect
via
induct
innat
immun
sinc
surviv
pmotreat
monkey
low
undetect
viremia
follow
infect
assess
immun
respons
surviv
monkey
ebov
challeng
surviv
rhesu
monkey
high
level
antiebov
antibodi
cell
respons
similar
pmoprotect
mice
unpublish
data
discuss
ebov
infect
repres
signific
public
health
threat
reliabl
effect
chemotherapeut
current
studi
indic
effect
pmo
target
specif
ebov
mrna
vitro
rodent
nonhuman
primat
ebov
infect
data
present
line
work
hypothesi
combin
pmo
target
multipl
viral
gene
slow
ebov
replic
allow
enough
time
develop
antivir
immun
respons
viral
clearanc
cellfre
experi
demonstr
ebovspecif
pmo
effici
inhibit
ebov
mrna
translat
marvspecif
pmo
effect
translat
correspond
ebov
gene
reporterbas
vitro
assay
appear
good
indic
sequencespecif
activ
pmo
seem
case
ebov
vitro
translat
assay
fulli
predict
rodent
efficaci
data
use
cell
show
ebov
replic
moder
suppress
cell
treat
ebovspecif
pmo
howev
visibl
differ
observ
compar
abil
singl
pmo
combin
three
pmo
reduc
viral
growth
pmo
use
studi
conjug
peptid
facilit
cellular
uptak
observ
lower
cellular
uptak
nake
pmo
compar
peptideconjug
pmo
vero
cell
unpublish
data
may
explain
moder
inhibit
observ
vitro
replic
assay
nonetheless
data
summar
figur
clearli
indic
feasibl
specif
gene
target
unconjug
pmo
favor
antivir
activ
compound
present
data
demonstr
therapeut
intervent
interfer
viral
replic
hypothes
efficaci
strategi
reli
abil
pmo
reduc
viral
replic
creat
window
opportun
immun
system
clear
otherwis
lethal
infect
approach
result
steril
protect
evidenc
robust
antiebov
immun
respons
surviv
mice
nonhuman
primat
mild
clinic
sign
thrombocytopenia
liver
enzym
elev
depress
lethargi
observ
pmotreat
monkey
like
success
treatment
patient
infect
ebov
requir
multifacet
approach
consist
antivir
therapeut
symptom
diseas
manag
postexposur
treatment
pmo
efficaci
ebov
rodent
presum
explain
pharmacokinet
properti
pmo
follow
parenter
inject
pmo
clear
bloodstream
within
hour
accumul
remain
within
tissu
spleen
liver
day
unpublish
data
administ
pmo
challeng
like
higher
concentr
avail
circul
tissu
peak
viral
replic
thu
pmo
may
abl
reduc
amplif
ebov
critic
timefram
allow
develop
appropri
host
immun
respons
otherwis
lethal
viral
infect
sinc
effect
treatment
seem
requir
critic
time
pmo
administr
nonhuman
primat
highli
sensit
ebov
infect
decid
pretreat
administ
daili
dose
pmo
viral
challeng
proofofconcept
nonhuman
primat
studi
shortterm
stabil
vivo
unfavor
properti
potenti
therapeut
note
deadli
acut
infect
short
period
treatment
clinic
repeat
administr
lifesav
drug
entir
feasibl
along
line
futur
studi
may
show
pharmacokinet
pmo
enhanc
modif
altern
rout
administr
regimen
improv
efficaci
order
corrobor
vitro
data
narrow
number
antivir
lead
candid
ebov
mous
model
obviou
choic
test
multipl
candid
pmo
mous
model
sever
differ
pathogenesi
compar
ebov
infect
nonhuman
primat
human
wide
accept
appropri
model
rapid
test
potenti
antivir
proceed
nhp
trial
differ
patholog
may
sever
hamper
predict
valu
mous
studi
use
therapeut
strategi
reli
target
mousespecif
virushost
interact
patholog
respons
rodent
intervent
target
viral
replic
evalu
high
degre
confid
model
antivir
efficaci
rodent
may
alway
predict
efficaci
nonhuman
primat
although
antivir
compound
unsuccess
rodent
like
also
fail
nonhuman
primat
justifi
initi
screen
rodent
model
initi
drugdiscoveri
strategi
identifi
druggabl
efficaci
antifiloviru
pmo
proofofprincipl
studi
use
pmo
demonstr
favor
antiebov
activ
vitro
vivo
thu
molecul
repres
pool
potenti
lead
compound
evalu
optim
futur
studi
focu
determin
favor
pmo
dose
regimen
also
therapeut
potenti
molecul
addit
antisens
pmo
design
target
region
within
ebov
genom
pursu
genet
design
microbi
therapeut
antisens
pmo
sequencebas
approach
allow
quick
hittolead
optim
may
acceler
timetodrug
develop
togeth
strategi
could
result
highli
efficaci
therapeut
treatment
regimen
lethal
viral
infect
nucleotidebas
antivir
pmo
easili
produc
larg
quantiti
alreadi
test
human
clinic
trial
appropri
safeti
profil
use
human
result
present
farreach
implic
treatment
highli
lethal
hemorrhag
fever
virus
diseas
caus
mani
acut
viral
diseas
includ
sar
influenza
dengu
emerg
pathogen
pmo
pmo
design
sequenc
homolog
near
overlap
aug
translat
start
site
ebov
use
control
experi
pmo
synthes
avi
biopharma
corval
oregon
unit
state
previous
describ
vitro
translat
assay
protein
code
sequenc
firefli
luciferas
without
initiatormet
codon
atg
subclon
multipl
clone
site
plasmid
pcineo
promega
madison
wisconsin
unit
state
subsequ
complementari
oligonucleotid
ebov
base
ebov
base
ebov
l
base
duplex
subclon
nhe
sal
site
singl
aug
viral
sequenc
leader
frame
code
sequenc
luciferas
plasmid
linear
vitro
transcrib
rna
produc
use
polymerasebas
megascript
kit
protocol
ambion
austin
texa
unit
state
vitro
translat
carri
program
reaction
transcrib
rna
final
concentr
nm
previous
describ
averag
light
unit
produc
set
reaction
treatment
normal
mean
wateronli
control
reaction
express
rel
light
unit
compar
luciferas
signal
control
reaction
vitro
assess
viral
replic
presenc
pmo
vero
cell
grown
confluenc
plate
day
indic
pmo
ad
serumfre
emem
h
emem
contain
fetal
calf
serum
ad
final
concentr
lm
l
combin
three
pmo
day
medium
remov
cell
one
multipl
infect
ebovzair
ad
well
serumfre
emem
h
viral
inoculum
remov
cell
wash
twice
pb
pmo
reintroduc
hs
serumfre
emem
brought
total
ml
emem
contain
fetal
calf
serum
supernat
remov
cell
hpi
viral
titer
determin
standard
plaqu
assay
anim
mice
age
wk
sex
obtain
nation
cancer
institut
frederick
cancer
research
develop
center
frederick
maryland
unit
state
mice
hous
microisol
cage
provid
autoclav
water
chow
ad
libitum
mice
challeng
intraperiton
inject
pfu
mouseadapt
ebov
dilut
phosphat
buffer
salin
pb
unless
otherwis
note
mice
treat
h
h
prior
ebov
challeng
mg
mg
ebov
marv
l
pmo
combin
pmo
unrel
pmo
one
present
studi
pmo
mg
administ
singl
dose
h
h
challeng
previous
show
ebola
viruslik
particl
given
h
viral
challeng
protect
mice
lethal
ebov
infect
therefor
comparison
postchalleng
immun
respons
group
mice
inject
viruslik
particl
h
ebov
challeng
mice
challeng
intraperiton
plaqueform
unit
mouseadapt
ebov
femal
hartley
guinea
pig
g
weight
obtain
charl
river
laboratori
wilmington
massachusett
unit
state
quarantin
us
armi
research
institut
infecti
diseas
least
h
manipul
determin
efficaci
pmo
guinea
pig
anim
treat
intraperiton
singl
dose
l
pmo
h
h
h
subcutan
challeng
pfu
guineapig
adapt
ebov
day
guinea
pig
bled
retroorbit
sinu
plasma
sampl
assess
viral
titer
plaqu
assay
femal
rhesu
macaqu
kg
weight
challeng
pfu
ebovzair
strain
intramuscular
inject
follow
pmo
treatment
monkey
treat
day
day
via
combin
parenter
rout
treatment
schedul
see
figur
dose
pmo
mg
inject
dose
l
pmo
rang
mg
per
inject
monkey
studi
found
siv
herp
bneg
test
prior
initi
studi
monkey
present
red
bleed
vagin
area
day
post
infect
estru
statu
monkey
studi
unknown
although
present
vagin
bleed
throughout
monitor
studi
number
anim
group
determin
help
statistician
order
use
least
number
anim
possibl
yet
still
statist
power
necessari
allow
meaning
interpret
data
produc
ebovinfect
anim
handl
maximum
contain
laboratori
us
armi
medic
research
institut
infecti
diseas
research
conduct
complianc
anim
welfar
act
feder
statut
regul
relat
anim
experi
involv
anim
adher
principl
state
nation
research
council
guid
care
use
laboratori
anim
facil
research
conduct
fulli
accredit
associ
assess
accredit
laboratori
anim
care
intern
hematolog
patholog
sampl
blood
sampl
obtain
anesthesia
cardiac
punctur
mice
femor
vein
monkey
viremia
assay
tradit
plaqu
assay
hematolog
cytokin
dimer
level
well
liverassoci
enzym
measur
previous
describ
day
day
ebov
infect
gross
necropsi
perform
three
mice
group
pretreat
either
combin
pmo
scrambl
pmo
tissu
collect
neutral
buffer
formalin
held
laboratori
minimum
tissu
decontamin
embed
paraffin
section
histolog
section
stain
hematoxylin
eosin
routin
light
microscopi
expos
ebovspecif
antisera
identifi
viral
antigen
within
tissu
sampl
immun
respons
follow
ebov
infect
blood
collect
surviv
mice
monkey
respect
ebov
challeng
level
ebovspecif
antibodi
determin
serum
plasma
sampl
previous
describ
antibodi
titer
defin
reciproc
highest
dilut
give
net
optic
densiti
valu
epitop
recogn
cell
surviv
mice
determin
previous
describ
briefli
ebovspecif
respons
analyz
cultur
splenocyt
lg
overlap
peptid
repres
gp
ebov
mimotop
clayton
victoria
australia
ngml
phorbol
lgml
ionomycin
complet
rpmi
contain
lgml
brefeldin
h
cultur
cell
stain
pharmingen
san
diego
california
unit
state
brefeldin
cell
surfac
stain
cell
fix
formaldehyd
permeabil
saponin
stain
antiifnc
pe
pharmingen
statist
analysi
compar
surviv
rate
rodent
experi
use
fisher
exact
test
stepdown
bootstrap
adjust
guinea
pig
experi
viral
titer
analyz
anova
post
hoc
dunnett
test
effect
viral
titer
surviv
analyz
logist
regress
p
valu
consid
signific
